Tiprelestat

Drug Profile

Tiprelestat

Alternative Names: Elafin

Latest Information Update: 04 Oct 2015

Price : $50

At a glance

  • Originator Proteo Biotech
  • Developer Proteo Biotech; Rhein Minapharm Biogenetics; Stanford University
  • Class Antipsoriatics; Recombinant proteins
  • Mechanism of Action Leucocyte elastase inhibitors; Myeloblastin inhibitors; Pancreatic elastase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary hypertension; Oesophageal cancer; Postoperative inflammation
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Myocardial reperfusion injury; Postoperative inflammation
  • Preclinical Lung disorders; Lung transplant rejection; Pulmonary hypertension

Most Recent Events

  • 04 Oct 2015 No recent reports of development identified - Phase-II for Postoperative inflammation (Prevention) in Egypt (IV)
  • 04 Oct 2015 No recent reports of development identified - Phase-II for Postoperative inflammation in Germany (IV)
  • 13 Aug 2015 Phase II development for Myocardial reperfusion injury (Prevention) is ongoing in the United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top